Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE CARD: NK1R+ MSCs for COVID-19 ARDS Recovery
NCT05491681Phase 1Withdrawn
- Sponsor
- BioCardia, Inc.
- Start
- Jan 2026
- Primary completion
- Jan 2026
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label trial of NK1R+ mesenchymal stem cells in acute respiratory distress syndrome (ARDS) (3 arms), sponsored by BioCardia, Inc. Primary endpoint: Number of product related adverse events at 3 months. Planned start Jan 2026; status: withdrawn.
02
Drugs
NK1R+ mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05491681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491681.